Medtronic PLC Stock Price, News & Analysis (NYSE:MDT)

$79.49 0.23 (0.29 %)
(As of 11/18/2017 04:00 PM ET)
Previous Close$79.49
Today's Range$80.09 - $78.74
52-Week Range$69.35 - $89.72
Volume7.09 million shs
Average Volume5.62 million shs
Market Capitalization$107.67643 billion
P/E Ratio16.95
Dividend Yield2.31%
Beta1

About Medtronic PLC (NYSE:MDT)

Medtronic PLC logoMedtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.


Industry, Sector and Symbol:
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Sector: Medical
  • Symbol: NYSE:MDT
  • CUSIP: 58505510
  • Web: www.medtronic.com
Debt:
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 1.64%
  • Quick Ratio: 1.40%
Price-To-Earnings:
  • Trailing P/E Ratio: 16.95
  • Forward P/E Ratio: 16.91
  • P/E Growth: 2.16
Sales & Book Value:
  • Annual Sales: $29.71 billion
  • Price / Sales: 3.62
  • Cash Flow: $6.81 per share
  • Price / Cash: 11.67
  • Book Value: $36.83 per share
  • Price / Book: 2.16
Dividend:
  • Annual Dividend: $1.84
  • Dividend Yield: 2.3%
Profitability:
  • Trailing EPS: $2.97
  • Net Income: $4.028 billion
  • Net Margins: 13.75%
  • Return on Equity: 12.92%
  • Return on Assets: 6.56%
Misc:
  • Employees: 91,000
  • Outstanding Shares: 1,354,590,000
 

Frequently Asked Questions for Medtronic PLC (NYSE:MDT)

What is Medtronic PLC's stock symbol?

Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic PLC pay dividends? What is the dividend yield for Medtronic PLC?

Medtronic PLC declared a quarterly dividend on Monday, August 28th. Shareholders of record on Friday, September 29th will be paid a dividend of $0.46 per share on Friday, October 20th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.31%. The ex-dividend date of this dividend is Thursday, September 28th. View Medtronic PLC's Dividend History.

How will Medtronic PLC's stock buyback program work?

Medtronic PLC announced that its Board of Directors has authorized a stock buyback plan on Thursday, October 5th 2017, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 49% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's management believes its stock is undervalued.

How were Medtronic PLC's earnings last quarter?

Medtronic PLC (NYSE:MDT) issued its quarterly earnings data on Tuesday, August, 22nd. The medical technology company reported $1.12 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.08 by $0.04. The medical technology company earned $7.39 billion during the quarter, compared to analysts' expectations of $7.44 billion. Medtronic PLC had a net margin of 13.75% and a return on equity of 12.92%. The firm's quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the business posted $1.03 EPS. View Medtronic PLC's Earnings History.

When will Medtronic PLC make its next earnings announcement?

Medtronic PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Medtronic PLC.

What guidance has Medtronic PLC issued on next quarter's earnings?

Medtronic PLC updated its second quarter earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $1.04 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.94. The company issued revenue guidance of ~$7.1 billion, compared to the consensus revenue estimate of $6.87 billion.

Where is Medtronic PLC's stock going? Where will Medtronic PLC's stock price be in 2017?

22 brokerages have issued 12 month price objectives for Medtronic PLC's stock. Their predictions range from $78.00 to $96.00. On average, they anticipate Medtronic PLC's stock price to reach $88.00 in the next twelve months. View Analyst Ratings for Medtronic PLC.

What are Wall Street analysts saying about Medtronic PLC stock?

Here are some recent quotes from research analysts about Medtronic PLC stock:

  • 1. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)
  • 2. According to Zacks Investment Research, "Over the last three months, Medtronic has been observed to underperform the broader industry. We note that, escalating costs and expenses are weighing on margins. Also, unfavorable foreign exchange continues to remain a drag. On a positive note,  we observe that apart from displaying successful integration and achievement of synergy targets, Medtronic’s major business groups continue to contribute to top-line growth which highlighted sustainability across all segments and geographies. Recently, the company announced the receipt of regulatory approval from the Japanese MHLW for its IN.PACT Admiral Drug-Coated Balloon. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside. We are also encouraged by the solid growth trend, continuing in the U.S. as well as the healthy global acceptance of its advanced therapies." (9/12/2017)
  • 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
  • 4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)
  • 5. Evercore ISI analysts commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock multiple (3-6x discount to peer group) was see-sawing precariously at ~15-16x P/E. While the bar had been lowered, MDT needed to deliver to flawless Q to instill investor confidence and start the path towards multiple correction (vs. group). The company began its first step, highlighted by a solid revenue beat, driven by high single digit growth in CR&HF. This is a key segment, and the ~8% growth should provide comfort against the bear thesis of competitive share losses / replacement cycle headwinds. We were also encouraged to see ~30% growth in TAVR, and a full rollout of the 34mm valve (launched only in 50% of centers) plus Intermediate Risk approval in early 2018 bodes well. Other key drivers in 2018 include the full commercial launch of 670G in Diabetes, Resolute Onyx launch, continued growth in AF, Link, DCBs, and the continued turnaround in Spine provides incremental confidence in MDT being able to sustain ~4% organic topline in the medium term. The second leg of value creation will rest on margin expansion, with the ST still skeptical of the company's ability to show margin expansion on a reported basis (including the impact of Fx hedges). We believe that the margin expansion thesis will play out in 2018, and will play a huge role in MDT's ability to close its P/E gap vs. peer group average. We expect this combination of a potential multiple reflation trade along with upside from capital deployment (incremental ~$3 Bn could potentially be accessible in near term post IRS settlement) to drive value for investors over the next 12 months." (2/21/2017)

Who are some of Medtronic PLC's key competitors?

Who owns Medtronic PLC stock?

Medtronic PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (1.76%), Bank of New York Mellon Corp (1.08%), Wells Fargo & Company MN (0.91%), Ameriprise Financial Inc. (0.84%), American Century Companies Inc. (0.67%) and Dimensional Fund Advisors LP (0.65%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic PLC.

Who sold Medtronic PLC stock? Who is selling Medtronic PLC stock?

Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, APG Asset Management N.V., Capital Guardian Trust Co., Vaughan Nelson Investment Management L.P., Capital Bank & Trust Co, Country Trust Bank, California State Teachers Retirement System and State of Tennessee Treasury Department. Company insiders that have sold Medtronic PLC company stock in the last year include Bryan C Hanson, Hoedt Rob Ten, Hooman Hakami and Omar Ishrak. View Insider Buying and Selling for Medtronic PLC.

Who bought Medtronic PLC stock? Who is buying Medtronic PLC stock?

Medtronic PLC's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, American Century Companies Inc., Asset Management One Co. Ltd., Ameriprise Financial Inc., Stifel Financial Corp, Allianz Asset Management GmbH, Boston Partners and Diamond Hill Capital Management Inc.. Company insiders that have bought Medtronic PLC stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic PLC.

How do I buy Medtronic PLC stock?

Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic PLC's stock price today?

One share of Medtronic PLC stock can currently be purchased for approximately $79.49.

How big of a company is Medtronic PLC?

Medtronic PLC has a market capitalization of $107.67643 billion and generates $29.71 billion in revenue each year. The medical technology company earns $4.028 billion in net income (profit) each year or $2.97 on an earnings per share basis. Medtronic PLC employs 91,000 workers across the globe.

How can I contact Medtronic PLC?

Medtronic PLC's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


MarketBeat Community Rating for Medtronic PLC (NYSE MDT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  849 (Vote Outperform)
Underperform Votes:  548 (Vote Underperform)
Total Votes:  1,397
MarketBeat's community ratings are surveys of what our community members think about Medtronic PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Medtronic PLC (NYSE:MDT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 10 Hold Ratings, 12 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $88.00 (10.71% upside)

Consensus Price Target History for Medtronic PLC (NYSE:MDT)

Price Target History for Medtronic PLC (NYSE:MDT)

Analysts' Ratings History for Medtronic PLC (NYSE:MDT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Needham & Company LLCReiterated RatingBuy$94.00N/AView Rating Details
11/3/2017SunTrust Banks, Inc.Reiterated RatingBuy$96.00N/AView Rating Details
11/3/2017Cowen and CompanyReiterated RatingBuy$95.00N/AView Rating Details
10/10/2017BMO Capital MarketsReiterated RatingOutperform$92.00 -> $89.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingMarket Perform$88.00 -> $85.00N/AView Rating Details
10/9/2017Stifel NicolausLower Price TargetHold$91.00 -> $83.00N/AView Rating Details
10/9/2017Royal Bank Of CanadaLower Price TargetOutperform -> Outperform$90.00 -> $85.00N/AView Rating Details
10/9/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$93.00 -> $83.00N/AView Rating Details
9/28/2017Jefferies Group LLCReiterated RatingBuy$96.00LowView Rating Details
8/23/2017Barclays PLCLower Price TargetOverweight$94.00 -> $92.00LowView Rating Details
8/22/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$92.00MediumView Rating Details
7/31/2017Deutsche Bank AGSet Price TargetBuy$96.00LowView Rating Details
7/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
5/30/2017Morgan StanleyBoost Price TargetEqual Weight$84.00 -> $86.00LowView Rating Details
5/28/2017Evercore ISIReiterated RatingOutperform$88.50 -> $91.00LowView Rating Details
5/26/2017CIBCReiterated RatingBuyLowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$87.00LowView Rating Details
4/20/2017Northland SecuritiesReiterated RatingHold$80.00MediumView Rating Details
3/20/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
2/22/2017WedbushReiterated RatingNeutral$85.00N/AView Rating Details
1/3/2017Bank of America CorporationDowngradeBuy -> Neutral$78.00N/AView Rating Details
1/3/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$84.00 -> $79.00N/AView Rating Details
8/25/2016Credit Suisse GroupReiterated RatingOutperform$92.00N/AView Rating Details
8/23/2016Citigroup Inc.Initiated CoverageBuy$63.98 -> $102.00N/AView Rating Details
6/20/2016ArgusReiterated RatingHold -> HoldN/AView Rating Details
6/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$93.00 -> $94.00N/AView Rating Details
6/8/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$86.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Medtronic PLC (NYSE:MDT)

Earnings by Quarter for Medtronic PLC (NYSE:MDT)

Earnings History by Quarter for Medtronic PLC (NYSE MDT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2017$1.07N/AView Earnings Details
8/22/20177/31/2017$1.08$1.12$7.44 billion$7.39 billionViewN/AView Earnings Details
5/25/2017Q4 17$1.31$1.33$7.86 billion$7.92 billionViewN/AView Earnings Details
2/21/20171/31/2017$1.11$1.12$7.22 billion$7.28 billionViewListenView Earnings Details
11/22/2016Q217$1.11$1.12$7.46 billion$7.35 billionViewListenView Earnings Details
8/25/2016Q117$1.01$1.03$7.17 billion$7.20 billionViewListenView Earnings Details
5/31/2016Q416$1.26$1.27$7.49 billion$7.57 billionViewListenView Earnings Details
3/1/2016Q316$1.06$1.06$6.99 billion$6.93 billionViewListenView Earnings Details
12/3/2015Q216$1.00$1.03$7.08 billion$7.06 billionViewListenView Earnings Details
9/3/2015Q116$1.01$1.02$7.03 billion$7.27 billionViewListenView Earnings Details
6/2/2015Q415$1.11$1.16$7.18 billion$7.30 billionViewListenView Earnings Details
2/17/2015Q3$0.97$1.01$4.25 million$4.32 millionViewListenView Earnings Details
11/18/2014Q2$0.96$0.96$4.37 million$4.40 millionViewListenView Earnings Details
8/19/2014Q115$0.92$0.93$4.25 billion$4.27 billionViewListenView Earnings Details
5/20/2014Q414$1.12$1.12$4.58 billion$4.60 billionViewListenView Earnings Details
2/18/2014Q314$0.91$0.91$4.15 billion$4.20 billionViewListenView Earnings Details
11/19/2013Q214$0.90$0.91$4.18 billion$4.20 billionViewListenView Earnings Details
8/20/2013Q1 2014$0.88$0.88$4.11 billion$4.10 billionViewListenView Earnings Details
5/21/2013Q4 2013$1.03$1.10$4.39 billion$4.50 billionViewListenView Earnings Details
2/19/2013Q3 2013$0.91$0.93$4.03 billion$4.03 billionViewListenView Earnings Details
11/20/20120.88$0.88$4.10 billionViewN/AView Earnings Details
8/21/2012$0.85$0.85ViewN/AView Earnings Details
5/22/2012$0.98$0.99ViewN/AView Earnings Details
2/21/2012$0.84$0.88ViewN/AView Earnings Details
11/22/2011$0.82$0.84ViewN/AView Earnings Details
8/23/2011$0.79$0.79ViewN/AView Earnings Details
5/24/2011$0.93$0.90ViewN/AView Earnings Details
2/22/2011$0.84$0.86ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Medtronic PLC (NYSE:MDT)
2017 EPS Consensus Estimate: $4.62
2018 EPS Consensus Estimate: $4.73
2019 EPS Consensus Estimate: $5.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20177$1.00$1.15$1.03
Q2 20177$1.10$1.37$1.16
Q3 20177$1.10$1.15$1.12
Q4 20177$1.29$1.34$1.31
Q1 20186$1.07$1.15$1.10
Q2 20187$0.89$1.20$1.03
Q3 20187$1.14$1.24$1.18
Q4 20187$1.35$1.46$1.41
Q1 20193$1.16$1.20$1.17
Q2 20193$1.08$1.26$1.17
Q3 20193$1.29$1.34$1.31
Q4 20193$1.53$1.57$1.55
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Medtronic PLC (NYSE:MDT)

Most Recent Dividend:10/20/2017
Annual Dividend:$1.84
Dividend Yield:2.31%
Dividend Growth:24.20% (3 Year Average)
Payout Ratio:61.95% (Trailing 12 Months of Earnings)
39.15% (Based on This Year's Estimates)
36.08% (Based on Next Year's Estimates)
Track Record:39 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Medtronic PLC (NYSE:MDT)

Dividend History by Quarter for Medtronic PLC (NYSE MDT)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/28/2017Quarterly$0.462.31%9/28/20179/29/201710/20/2017
6/23/2017Quarterly$0.462.07%7/5/20177/7/20177/26/2017
3/10/2017Quarterly$0.432.08%3/22/20173/24/20174/13/2017
12/9/2016quarterly$0.432.33%12/21/201612/23/20161/13/2017
8/22/2016Quarterly$0.431.98%9/27/20169/29/201610/21/2016
6/24/2016quarterly$0.431.85%7/6/20167/8/20167/27/2016
2/22/2016quarterly$0.381.98%3/22/20163/24/20164/15/2016
12/11/2015quarterly$0.381.96%12/22/201512/24/20151/15/2016
8/21/2015quarterly$0.382.18%9/23/20159/25/201510/16/2015
6/19/2015quarterly$0.381.97%6/25/20156/29/20157/17/2015
2/20/2015quarterly$0.311.55%3/26/20153/30/20154/17/2015
12/4/2014$0.3112/30/20141/2/20151/16/2015
12/5/2014quarterly$0.311.63%12/30/20141/2/20151/6/2015
8/21/2014quarterly$0.311.92%10/1/201410/3/201410/24/2014
6/16/2014quarterly$0.311.98%7/1/20147/3/20147/25/2014
2/14/2014quarterly$0.281.97%4/2/20144/4/20144/25/2014
12/5/2013quarterly$0.281.93%12/31/20131/3/20141/24/2014
8/22/2013quarterly$0.282.12%10/2/201310/4/201310/25/2013
6/21/2013quarterly$0.282.13%7/2/20137/5/20137/26/2013
2/15/2013quarterly$0.262.21%4/3/20134/5/20134/26/2013
12/9/2012quarterly$0.262.44%12/13/201212/17/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Medtronic PLC (NYSE MDT)

Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 81.14%
Insider Trades by Quarter for Medtronic PLC (NYSE:MDT)
Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Insider Trades by Quarter for Medtronic PLC (NYSE MDT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017Bryan C. HansonEVPSell16,000$79.02$1,264,320.00View SEC Filing  
10/16/2017Bryan C HansonEVPSell16,000$78.03$1,248,480.00View SEC Filing  
9/15/2017Omar IshrakCEOSell140,407$81.63$11,461,423.41View SEC Filing  
7/17/2017Bryan C. HansonEVPSell12,000$88.57$1,062,840.00View SEC Filing  
6/21/2017Richard H AndersonDirectorBuy5,600$88.90$497,840.00View SEC Filing  
3/20/2017Hoedt Rob TenEVPSell50,757$81.58$4,140,756.06View SEC Filing  
3/15/2017Omar IshrakCEOSell95,000$82.82$7,867,900.00View SEC Filing  
3/2/2017Hooman HakamiEVPSell52,316$82.33$4,307,176.28View SEC Filing  
12/13/2016Robert C. PozenDirectorBuy13,660$73.21$1,000,048.60View SEC Filing  
11/23/2016James T. LenehanDirectorBuy2,000$73.27$146,540.00View SEC Filing  
9/27/2016Richard KuntzVPSell17,141$86.70$1,486,124.70View SEC Filing  
9/26/2016Richard KuntzVPSell25,199$86.67$2,183,997.33View SEC Filing  
9/15/2016Kendall J. PowellDirectorSell7,907$85.45$675,653.15View SEC Filing  
9/15/2016Omar IshrakCEOSell61,925$84.93$5,259,290.25View SEC Filing  
8/29/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/26/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/15/2016Geoffrey MarthaEVPSell3,766$88.26$332,387.16View SEC Filing  
7/13/2016Gary Lee EllisEVPSell35,495$88.64$3,146,276.80View SEC Filing  
7/13/2016Shirley A JacksonDirectorSell2,104$88.64$186,498.56View SEC Filing  
7/6/2016Carol A. SurfaceSVPSell9,787$87.08$852,251.96View SEC Filing  
7/5/2016Bryan C. HansonEVPSell15,272$87.11$1,330,343.92View SEC Filing  
6/3/2016Richard KuntzVPSell49,905$82.60$4,122,153.00View SEC Filing  
4/1/2016Richard KuntzVPSell4,000$75.22$300,880.00View SEC Filing  
3/18/2016Shirley A JacksonDirectorSell1,238$75.60$93,592.80View SEC Filing  
3/17/2016Omar IshrakCEOSell23,799$76.15$1,812,293.85View SEC Filing  
3/4/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
2/5/2016Bryan C. HansonEVPSell5,000$76.14$380,700.00View SEC Filing  
1/8/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
12/4/2015Richard KuntzVPSell13,715$78.06$1,070,592.90View SEC Filing  
9/15/2015Omar IshrakCEOSell20,000$69.43$1,388,600.00View SEC Filing  
7/14/2015Carol A SurfaceSVPSell13,722$75.83$1,040,539.26View SEC Filing  
4/6/2015Richard KuntzVPSell31,768$77.39$2,458,525.52View SEC Filing  
3/25/2015Gary Lee EllisCFOSell43,183$77.81$3,360,069.23View SEC Filing  
3/13/2015Omar IshrakCEOSell20,000$76.24$1,524,800.00View SEC Filing  
2/19/2015Christopher J OconnellEVPSell50,361$78.22$3,939,237.42View SEC Filing  
12/19/2014Richard KuntzVPSell12,855$74.54$958,211.70View SEC Filing  
12/2/2014Shirley A JacksonDirectorSell1,102$74.43$82,021.86View SEC Filing  
11/28/2014Christopher J OconnellEVPSell42,921$73.95$3,174,007.95View SEC Filing  
10/6/2014Christopher J OconnellEVPSell15,388$64.98$999,912.24View SEC Filing  
8/26/2014Christopher J OconnellEVPSell28,000$63.57$1,779,960.00View SEC Filing  
8/26/2014Shirley A JacksonDirectorSell2,769$63.66$176,274.54View SEC Filing  
4/17/2014Catherine SzymanVPSell29,420$58.79$1,729,601.80View SEC Filing  
4/9/2014Richard KuntzVPSell2,512$60.98$153,181.76View SEC Filing  
4/1/2014Gary Lee EllisCFOSell4,246$61.48$261,044.08View SEC Filing  
3/28/2014Christopher OconnellEVPSell1,982$60.39$119,692.98View SEC Filing  
3/20/2014Catherine SzymanVPSell14,979$59.57$892,299.03View SEC Filing  
3/14/2014Omar IshrakCEOSell10,000$59.12$591,200.00View SEC Filing  
3/10/2014Neil AyotteVPSell1,845$59.64$110,035.80View SEC Filing  
12/4/2013Neil AyotteVPSell1,729$57.14$98,795.06View SEC Filing  
9/13/2013Omar IshrakCEOSell10,000$53.58$535,800.00View SEC Filing  
8/26/2013Catherine SzymanVPSell56,998$52.60$2,998,094.80View SEC Filing  
8/22/2013H James DallasVPSell32,332$53.19$1,719,739.08View SEC Filing  
8/21/2013H James DallasVPSell36,256$52.82$1,915,041.92View SEC Filing  
8/21/2013Shirley JacksonDirectorSell8,033$52.84$424,463.72View SEC Filing  
7/11/2013Christopher J OconnellEVPSell30,429$52.92$1,610,302.68View SEC Filing  
7/11/2013Gary Lee EllisCFOSell32,602$53.62$1,748,119.24View SEC Filing  
7/11/2013H James DallasVPSell69,889$53.72$3,754,437.08View SEC Filing  
7/1/2013H James DallasVPSell20,579$52.10$1,072,165.90View SEC Filing  
6/26/2013D Cameron FindlayVPSell75,042$52.20$3,917,192.40View SEC Filing  
6/19/2013H James DallasVPSell94,117$52.74$4,963,730.58View SEC Filing  
5/22/2013Richard H AndersonDirectorBuy4,800$52.32$251,136.00View SEC Filing  
5/10/2013Jack W SchulerDirectorSell34,230$48.24$1,651,255.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Medtronic PLC (NYSE MDT)

Source:
DateHeadline
Medtronic PLC (MDT) EVP Bryan C. Hanson Sells 16,000 SharesMedtronic PLC (MDT) EVP Bryan C. Hanson Sells 16,000 Shares
www.americanbankingnews.com - November 17 at 8:11 PM
Medtronic plc (MDT) and Integer Holdings Corporation (ITGR) Critical ReviewMedtronic plc (MDT) and Integer Holdings Corporation (ITGR) Critical Review
www.americanbankingnews.com - November 17 at 3:32 PM
Integer Holdings Corporation (ITGR) & Medtronic PLC (MDT) Head-To-Head ReviewInteger Holdings Corporation (ITGR) & Medtronic PLC (MDT) Head-To-Head Review
www.americanbankingnews.com - November 17 at 1:24 AM
Medtronic PLC (MDT) Receives Consensus Rating of "Hold" from BrokeragesMedtronic PLC (MDT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 16 at 5:06 PM
Critical Comparison: Medtronic PLC (MDT) vs. Integer Holdings Corporation (ITGR)Critical Comparison: Medtronic PLC (MDT) vs. Integer Holdings Corporation (ITGR)
www.americanbankingnews.com - November 15 at 1:38 PM
Medtronic (MDT) Rating Dropped to SellMedtronic (MDT) Rating Dropped to Sell
investorplace.com - November 14 at 9:53 AM
Medtronic PLC (MDT) Scheduled to Post Earnings on TuesdayMedtronic PLC (MDT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - November 14 at 2:08 AM
Medtronic to Present New Clinical Data on Vascular Interventions and Key Symposia at VEITHsymposium 2017Medtronic to Present New Clinical Data on Vascular Interventions and Key Symposia at VEITHsymposium 2017
finance.yahoo.com - November 13 at 8:52 PM
Q2 2018 Earnings Forecast for Medtronic PLC (MDT) Issued By William BlairQ2 2018 Earnings Forecast for Medtronic PLC (MDT) Issued By William Blair
www.americanbankingnews.com - November 13 at 6:34 AM
Medtronic PLC (MDT) Expected to Announce Quarterly Sales of $7.09 BillionMedtronic PLC (MDT) Expected to Announce Quarterly Sales of $7.09 Billion
www.americanbankingnews.com - November 12 at 10:22 AM
Medtronic Plc breached its 50 day moving average in a Bullish Manner : MDT-US : November 10, 2017Medtronic Plc breached its 50 day moving average in a Bullish Manner : MDT-US : November 10, 2017
finance.yahoo.com - November 12 at 6:02 AM
Markets Right Now: Eight-week streak ends as stocks slipMarkets Right Now: Eight-week streak ends as stocks slip
marketbeat.com - November 10 at 4:40 PM
Medtronic PLC (MDT) Issues Q2 Earnings GuidanceMedtronic PLC (MDT) Issues Q2 Earnings Guidance
www.americanbankingnews.com - November 10 at 8:34 AM
Medtronic PLC (MDT) Rating Reiterated by Needham & Company LLCMedtronic PLC (MDT) Rating Reiterated by Needham & Company LLC
www.americanbankingnews.com - November 9 at 9:34 AM
Medtronic (MDT) Prelim. Q2 Revenue Tops Views - StreetInsider.comMedtronic (MDT) Prelim. Q2 Revenue Tops Views - StreetInsider.com
www.streetinsider.com - November 8 at 10:41 PM
Medtronic Says Hurricanes Financial Hit Lighter Than ExpectedMedtronic Says Hurricane's Financial Hit Lighter Than Expected
finance.yahoo.com - November 8 at 10:41 PM
Oppenheimer Holdings Weighs in on Medtronic PLCs FY2019 Earnings (MDT)Oppenheimer Holdings Weighs in on Medtronic PLC's FY2019 Earnings (MDT)
www.americanbankingnews.com - November 8 at 9:52 PM
Medtronics Intellis CE MarkdMedtronic's Intellis CE Mark'd
seekingalpha.com - November 8 at 5:40 PM
Medtronic Announces Preliminary Second Quarter RevenueMedtronic Announces Preliminary Second Quarter Revenue
finance.yahoo.com - November 8 at 5:40 PM
Mazor Robotics Enters a New Era Mazor Robotics Enters a New Era
www.fool.com - November 8 at 12:19 PM
Metrics for Earnings Momentum Make Medtronic (MDT) a SellMetrics for Earnings Momentum Make Medtronic (MDT) a Sell
investorplace.com - November 7 at 10:04 AM
Medtronic Received CE Mark for Intellis Platform - BenzingaMedtronic Received CE Mark for Intellis Platform - Benzinga
www.benzinga.com - November 7 at 6:42 AM
Medtronic Received CE Mark for Intellis PlatformMedtronic Received CE Mark for Intellis Platform
feeds.benzinga.com - November 6 at 5:34 AM
Medtronic Receives CE Mark for the Worlds Smallest Fully Implantable Spinal Cord Stimulator and Announces ... - GlobeNewswire (press release)Medtronic Receives CE Mark for the World's Smallest Fully Implantable Spinal Cord Stimulator and Announces ... - GlobeNewswire (press release)
globenewswire.com - November 6 at 1:22 AM
Medtronic Receives CE Mark for the Worlds Smallest Fully Implantable Spinal Cord Stimulator and Announces European Launch of the Intellis PlatformMedtronic Receives CE Mark for the World's Smallest Fully Implantable Spinal Cord Stimulator and Announces European Launch of the Intellis Platform
finance.yahoo.com - November 6 at 1:22 AM
This Growing Robotics Company Is a Hit With Surgeons (Hint: It's not Intuitive Surgical)This Growing Robotics Company Is a Hit With Surgeons (Hint: It's not Intuitive Surgical)
finance.yahoo.com - November 5 at 8:21 PM
What Does Medtronic plc’s (MDT) Share Price Indicate?What Does Medtronic plc’s (MDT) Share Price Indicate?
finance.yahoo.com - November 5 at 6:12 AM
Medtronic PLC (MDT) Earns Buy Rating from SunTrust Banks, Inc.Medtronic PLC (MDT) Earns Buy Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - November 4 at 10:13 AM
Medtronic PLC (MDT) Given Buy Rating at Cowen and CompanyMedtronic PLC (MDT) Given Buy Rating at Cowen and Company
www.americanbankingnews.com - November 3 at 7:50 PM
Medtronic plc: Medtronic Evolut PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over TimeMedtronic plc: Medtronic Evolut PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over Time
www.finanznachrichten.de - November 3 at 5:01 PM
Medtronic Evolut(TM) PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over TimeMedtronic Evolut(TM) PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over Time
finance.yahoo.com - November 3 at 5:01 PM
Medtronic Releases Fiscal Year 2017 Integrated Performance ReportMedtronic Releases Fiscal Year 2017 Integrated Performance Report
finance.yahoo.com - November 3 at 5:00 PM
In surprise, study finds heart stents dont solve chest painIn surprise, study finds heart stents don't solve chest pain
finance.yahoo.com - November 3 at 5:00 PM
New Analyses Reinforce Hemodynamic Benefits of Medtronic Evolut(TM) TAVR Platform in Intermediate Risk Aortic Stenosis PatientsNew Analyses Reinforce Hemodynamic Benefits of Medtronic Evolut(TM) TAVR Platform in Intermediate Risk Aortic Stenosis Patients
globenewswire.com - November 2 at 6:19 AM
Independent Study Shows New Data on Shortened DAPT in STEMI Patients with Medtronic Resolute Integrity Drug-Eluting StentIndependent Study Shows New Data on Shortened DAPT in STEMI Patients with Medtronic Resolute Integrity Drug-Eluting Stent
finance.yahoo.com - November 2 at 6:18 AM
Medtronic Unveils Strong Early Outcomes for the Intrepid(TM) Transcatheter Mitral Valve Replacement (TMVR) SystemMedtronic Unveils Strong Early Outcomes for the Intrepid(TM) Transcatheter Mitral Valve Replacement (TMVR) System
finance.yahoo.com - November 2 at 6:18 AM
Earnings Visibility Metrics Keep Medtronic (MDT) Upgrade to Hold - Investorplace.comEarnings Visibility Metrics Keep Medtronic (MDT) Upgrade to Hold - Investorplace.com
investorplace.com - November 1 at 6:10 AM
Earnings Visibility Metrics Keep Medtronic (MDT) Upgrade to HoldEarnings Visibility Metrics Keep Medtronic (MDT) Upgrade to Hold
investorplace.com - October 31 at 9:44 AM
Medtronic Plc – Value Analysis (NYSE:MDT) : October 30, 2017Medtronic Plc – Value Analysis (NYSE:MDT) : October 30, 2017
finance.yahoo.com - October 31 at 3:41 AM
[$$] Sofinnova Partners Leads $14.3 Million Series A for Medtech Startup HighLife[$$] Sofinnova Partners Leads $14.3 Million Series A for Medtech Startup HighLife
finance.yahoo.com - October 31 at 3:41 AM
Dividend Aristocrats In Focus Part 24: Medtronic - Seeking AlphaDividend Aristocrats In Focus Part 24: Medtronic - Seeking Alpha
seekingalpha.com - October 28 at 8:03 AM
Medtronic Plc breached its 50 day moving average in a Bullish Manner : MDT-US : October 27, 2017Medtronic Plc breached its 50 day moving average in a Bullish Manner : MDT-US : October 27, 2017
finance.yahoo.com - October 28 at 8:03 AM
How Electricity Could Replace Opioids In Treating Chronic PainHow Electricity Could Replace Opioids In Treating Chronic Pain
finance.yahoo.com - October 28 at 8:03 AM
Medtronic Announces First Economic Analysis Demonstrating Benefits of Professional CGM in People with Type 2 DiabetesMedtronic Announces First Economic Analysis Demonstrating Benefits of Professional CGM in People with Type 2 Diabetes
finance.yahoo.com - October 27 at 6:48 AM
Shrinking Industry Group Rank Makes Medtronic (MDT) a Sell - Investorplace.comShrinking Industry Group Rank Makes Medtronic (MDT) a Sell - Investorplace.com
investorplace.com - October 25 at 7:08 AM
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & NephewZacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
finance.yahoo.com - October 25 at 7:08 AM
Shrinking Industry Group Rank Makes Medtronic (MDT) a SellShrinking Industry Group Rank Makes Medtronic (MDT) a Sell
investorplace.com - October 24 at 9:27 AM
Obamacares original sin is still the biggest problem with US health careObamacare's 'original sin' is still the biggest problem with US health care
www.cnbc.com - October 23 at 9:50 AM
 Analysts Anticipate Medtronic PLC (MDT) Will Post Quarterly Sales of $6.89 Billion Analysts Anticipate Medtronic PLC (MDT) Will Post Quarterly Sales of $6.89 Billion
www.americanbankingnews.com - October 23 at 3:20 AM
Medtronic PLC (MDT) Receives Consensus Recommendation of "Hold" from AnalystsMedtronic PLC (MDT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 6:42 PM

Social Media

Financials

Chart

Medtronic PLC (NYSE MDT) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.